[1]王惠文,刘瑞宝,李晓婧,等.载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例[J].介入放射学杂志,2021,30(06):568-571.
 WANG Huiwen,LIU Ruibao,LI Xiaojing,et al.Drug- eluting beads - TACE for the treatment of refractory liver metastases from synecological malignant tumors: preliminary results in 12 patients[J].journal interventional radiology,2021,30(06):568-571.
点击复制

载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年06
页码:
568-571
栏目:
肿瘤介入
出版日期:
2021-06-26

文章信息/Info

Title:
Drug- eluting beads - TACE for the treatment of refractory liver metastases from synecological malignant tumors: preliminary results in 12 patients
作者:
王惠文 刘瑞宝 李晓婧 何东风
Author(s):
WANG Huiwen LIU Ruibao LI Xiaojing HE Dongfeng.
Department of Intervention, Affiliated Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province 150081, China
关键词:
【关键词】 妇科恶性肿瘤肝转移经动脉化疗栓塞载药微球
文献标志码:
A
摘要:
【摘要】 目的 探索载药微球(DEB)-TACE治疗难治性妇科恶性肿瘤肝转移患者的安全性及短期疗效。方法 回顾性分析我院收治的难治性妇科恶性肿瘤肝转移患者12例,给予DEB-TACE治疗肝转移病灶,观察首次治疗后不良反应情况,采用改良实体瘤疗效评价标准评估治疗后3个月及6个月的疗效。结果 常见不良反应为细胞毒性反应、肝功一过性升高、发热、恶心呕吐及腹痛,不良反应集中在3级以下,无严重不良反应及与手术相关的死亡病例;术后3个月及6个月总缓解率(ORR)分别为75%,50%,疾病控制率(DCR)分别为91.7%,83.3%。结论 DEB-TACE治疗妇科恶性肿瘤肝转移患者安全,有效,值得临床进一步推广。

参考文献/References:

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[2] Wang MC, Zhang J, Ji SF, et al. Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review[J]. Breast, 2017, 36: 25-30.
[3] Thomas JV, Naguib NN, Lehnert T, et al. Initial experience with repetitive transarterial chemoembolization(TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient’s management[J]. Gynecol Oncol, 2012, 124: 225-229.
[4] 吴建兵.肝转移癌经动脉介入治疗进展[J].肝癌电子杂志,2018, 5:30-33.
[5] 周官辉,孙军辉,张岳林,等. HepaSphere载药微球栓塞治疗不可切除肝癌15例[J]. 介入放射学杂志, 2015, 24:869-872.
[6] 徐新建,滕 飞,杜洪涛. 伊立替康载药微球治疗结肠癌肝转移瘤的系统评价[J]. 中华介入放射学电子杂志, 2017, 5:273-281.
[7] Xing MZ, Kooby DA, El-Rayes BF, et al. Locoregional therapies for metastatic colorectal carcinoma to the liver: an evidence-based review[J]. J Surg Oncol, 2014, 110: 182-196.
[8] 刘 金,曹 刚,张根山,等. 国产CalliSpheres载药微球治疗原发性肝癌12例[J]. 介入放射学杂志, 2017, 26:993-998.
[9] Wu B, Zhou J, Ling G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study[J]. World J Surg Oncol, 2018, 16: 69.
[10] 翟 越,赵 卫,潘文秋,等. TACE联合载药微球治疗肝癌的研究进展[J]. 介入放射学杂志, 2019, 28:1211-1214.
[11] Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update[J]. Oncologist, 2019, 24: 990-1005.
[12] Xiao YB, Zhang B, Wu YL. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis[J]. J Zhejiang Univ Sci B, 2018, 19: 829-843.
[13] 王 勤,李 斌,石海峰,等. 射频消融治疗妇科恶性肿瘤转移性病变[J]. 中国介入影像与治疗学, 2015, 12:391-394.
[14] Rostas J, Tam A, Sato T, et al. Image- guided transarterial chemoembolization with Drug- Eluting Beads Loaded with Doxorubicin(DEBDOX) for unresectable hepatic metastases from melanoma: technique and outcomes[J]. Cardiovasc Intervent Radiol, 2017, 40: 1392-1400.
[15] 王 忠,刘启榆,杨 伟,等. 国产CalliSpheres载药微球DEB-TACE治疗无法手术肝癌的临床价值[J]. 肝脏, 2019, 24:767-770.
[16] Iezzi R, Marsico VA, Guerra A, et al. Trans- arterial chemoem-bolization with irinotecan- loaded drug- eluting beads(DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase Ⅱ single- center study[J]. Cardiovasc Intervent Radiol, 2015, 38: 1523-1531.
[17] Aliberti C,Carandina R,Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug- eluting beads for primary and metastatic liver cancer therapy[J]. Anticancer Res, 2016, 36:3515-3521.
[18] Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers[J]. Drug Deliv, 2017,24:1011-1017.
[19] 赵 倩,颜志平. 载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J]. 介入放射学杂志, 2017, 26:1052-1056.
[20] Liu YS, Lin CY,Chuang MT, et al. Five-year outcome of conventional and drug- eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. BMC Gastroenterol, 2018, 18: 124.
[21] Bhutiani N,Akinwande O,Martin RC. Efficacy and toxicity ofhepatic intra-arterialdrug- eluting(irinotecan) bead(DEBIRI) therapy in irinotecan- refractory unresectable colorectal liver metastases[J]. World J Surg, 2016, 40:1178-1190.
[22] Lin YT, Medioni J,Amouyal G, et al. Doxorubicin-loaded 70-150 μm microspheres for liver- dominant metastatic breast cancer: results and outcomes of a pilot study[J]. Cardiovasc Intervent Radiol, 2017, 40: 81-89.
[23] 白秀梅,杨 薇,严 昆. 乳腺癌肝转移治疗现状及射频消融的应用及前景[J]. 世界华人消化杂志, 2017, 25:1143-1149.

相似文献/References:

[1]李晓光,金征宇,杨宁,等.经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移[J].介入放射学杂志,2008,(11):803.
 LI Xiaoguang,JIN Zhengyu,YANG Ning,et al.Transcatheter arterial chemoperfusion or chemoembolizaiton for treatment of liver metastasis from malignant insulinoma[J].journal interventional radiology,2008,(06):803.
[2]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
 LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors:a therapeutic analysis[J].journal interventional radiology,2010,(06):442.
[3]于清泳,赵 辉.结直肠癌肝转移患者TACE治疗后含表皮生长因子的纤维蛋白样细胞外基质2水平及意义 [J].介入放射学杂志,2021,30(10):1035.
 YU Qingyong,ZHAO Hui..The level and significance of EGF containing fibulin-like extracellular matrix protein 2 in patients with liver metastases from colorectal cancer after TACE treatment[J].journal interventional radiology,2021,30(06):1035.

备注/Memo

备注/Memo:
(收稿日期:2020-03-28)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-06-25